Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation

摘要: Acute on chronic liver failure (ACLF) is a disease entity with high mortality rate. The acute event arises from drugs and toxins, viral infections, bacterial sepsis, interventions (both surgical non-surgical) vascular events top of known or occult disease. ACLF secondary to reactivation hepatitis B virus distinct condition; the which can be managed in wake new potent antiviral therapy. For example, lamivudine entecavir use has shown definite short-term survival benefits, even though drug resistance concern former. renoprotective effects telbivudine have been few studies useful presence renal dysfunction. Monotherapy newer agents such as tenofovir combination nucleos(t)ides promising for improving this special group patients. This review describes current status therapy patient due B, thereby providing an algorithm management